Biotec Pharmacon ASA   Report issue

For profit Phase 3
Founded: Tromso Norway (1990)
Status: No NME R&D (1990)

Organization Overview

First Clinical Trial
2003
NCT00289003
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2008

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (1)

beta-glucans (8 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 2)

Burns (Phase 1)

Diabetic Foot (Phase 3)

Foot Ulcer (Phase 3)

Head and Neck Neoplasms (Phase 3)

Leg Ulcer (Phase 2)

Lymphoma (Phase 1)

Lymphoma, Non-Hodgkin (Phase 1)

Mucositis (Phase 3)

Stomatitis (Phase 3)

Ulcer (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 8
  • # of Trial APIs: 1